Gilead Exercises Option on Kymera’s KT-200, Triggering $45M Milestone
Gilead Sciences exercised its option to license Kymera’s KT-200 degrader for CDK2, triggering a $45 million milestone payment and bringing Kymera’s collaboration proceeds to $85 million. Gilead will advance KT-200 into IND-enabling studies ahead of a planned 2027 IND filing.
1. Option Exercise and Milestone Payment
Gilead Sciences exercised its option under the collaboration to exclusively license KT-200, a first-in-class oral CDK2 molecular glue degrader discovered by Kymera, triggering a $45 million milestone payment and raising Kymera’s collaboration proceeds to $85 million to date.
2. KT-200 Development and IND Timeline
KT-200 demonstrated low-nanomolar CDK2 degradation, robust activity in CCNE1-amplified cell lines and in vivo tumor models, and favorable brain penetration and safety profiles; Gilead plans to advance the program into IND-enabling studies ahead of a 2027 IND filing.
3. Deal Structure and Financial Upside
Under the agreement Kymera is eligible for up to $750 million in total payments plus tiered royalties ranging from high single-digit to mid-teens, while Gilead holds global rights to develop, manufacture and commercialize all products arising from the collaboration.